Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adoptive TIL transfer in the adjuvant setting for melanoma: long-term patient survival.

Journal of immunology research - 1 Jan 2014

Khammari Amir, Knol Anne-Chantal, Nguyen Jean-Michel, Bossard Céline, Denis Marc-Guillaume, Pandolfino Marie-Christine, Quéreux Gaëlle, Bercegeay Sylvain, Dréno Brigitte

Abstract excerpt

Two first analyses of our clinical trial on TIL as adjuvant therapy for melanoma were published in 2002 and 2007. We present here an update of the clinical results after a 17-year median followup. In this trial, disease-free patients were randomly assigned to receive either TIL/IL-2 or IL-2. The relapse-free survival (RFS) was the primary objective. Eighty-eight patients were enrolled. A new analysis performed in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Follow-Up Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunophenotyping

Share to Immunotherapy, Adoptive

Share to Lymphocytes, Tumor-Infiltrating

Share to Melanoma

Share to Neoplasm Staging

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 24741578
DOI: 10.1155/2014/186212
PMCID: PMC3987883

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adoptive TIL transfer in the adjuvant setting for melanoma: long-term patient survival.PMID 24741578Read ↗

Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development.Semantic proximity Read ↗

Tissue biomarkers in melanoma patients treated with TIL.Semantic proximity Read ↗

Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).Semantic proximity Read ↗

Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanomaSemantic proximity Read ↗

Modeling ex vivo tumor-infiltrating lymphocyte expansion from established solid malignanciesSemantic proximity Read ↗

Characteristics and Developmental Trajectory of Clinical Trials Focused on Tumor-Infiltrating Lymphocytes for Cancer TreatmentSemantic proximity Read ↗

Exploiting the curative potential of adoptive T‐cell therapy for cancerSemantic proximity Read ↗

[he role of immunotherapy for the adjuvant treatment of BRAF-mutant melanoma].Semantic proximity Read ↗

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.Semantic proximity Read ↗

Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy.Semantic proximity Read ↗

Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs.Semantic proximity Read ↗

Successful ex vivo expansion of tumor infiltrating lymphocytes with systemic chemotherapy prior to surgical resectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.